RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramThe BRACELET-1 results reported a 12-month progression-free survival (PFS) rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirm/